EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
Anavo Therapeutics BV
Netherlands
- Leiden, South Holland
- 04/05/2023
- Seed
- $9,406,482
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.
We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.
Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
- Industry Biotechnology Research
- Website https://www.anavotx.com/
- LinkedIn https://www.linkedin.com/company/anavo-therapeutics-bv/
Related People
Birgit ZechFounder
Germany -
ND
• 20 years working experience in Biotech, 15+ years in Business Development
• In depth knowledge of the pharmaceutical and biotech industry
• Excellent track record in deal making and fundraising
• Strong network to leading Pharma and Biotech companies, significant partnering experience in EP, US and JP
• Over 5 years experience in IP management
• Strong background in chemistry (small molecules, kinase inhibitors, protein modeling) and biology (antibodies, next generation scaffolds)
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)